The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...

Indiana lawmakers are weighing new guardrails around drug compounding amid warnings that patients are receiving powerful prescription treatments in settings that operate largely outside state ...

The FDA announced Friday that it intends to restrict the active pharmaceutical ingredients of glucagon-like peptide-1 (GLP-1) receptor agonists used in unapproved compounded drugs that are being ...

Feb 5 (Reuters) - Hims & Hers said it would begin offering compounded versions of Novo Nordisk's Wegovy pill at an ...

Hims & Hers Health, Inc. faces volatile earnings as compounded GLP-1 setbacks pressure shares. Click for this HIMS stock earnings preview.

The FDA said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs from companies like Hims & Hers.

By Amina Niasse NEW YORK, Feb 5 (Reuters) - Online telehealth company Hims and Hers Health will start offering compounded copies of Novo Nordisk's new Wegovy weight-loss pill at an introductory price ...

Feb 6 (Reuters) - The U.S. Food and Drug Administration said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs that companies such as Hims & Hers and other ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or side effect disclosures. These compounded drugs, unlike generics, are not ...

Hims Hers Health announced on Saturday that it will stop offering access to its compounded semaglutide pill following a ...

OpenLoop, a company providing operational and tech services to telehealth companies, and compounding pharmacy Triad Rx are being sued in a class action for selling oral tirzepatide. | The complaint ...